These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 16555688)

  • 1. Clazosentan (Actelion).
    Uhlmann D
    Curr Opin Investig Drugs; 2006 Mar; 7(3):272-81. PubMed ID: 16555688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of the selective endothelin A (ET(A)) receptor antagonist Clazosentan on cerebral perfusion and cerebral oxygenation following severe subarachnoid hemorrhage - preliminary results from a randomized clinical series.
    Barth M; Capelle HH; Münch E; Thomé C; Fiedler F; Schmiedek P; Vajkoczy P
    Acta Neurochir (Wien); 2007; 149(9):911-8; discussion 918. PubMed ID: 17700991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of endothelin receptor antagonists on vasospasm following aneurysmal subarachnoid hemorrhage.
    Komotar RJ; Starke RM; Connolly ES
    Neurosurgery; 2011 Dec; 69(6):N13-4. PubMed ID: 22067343
    [No Abstract]   [Full Text] [Related]  

  • 4. Clazosentan: prevention of cerebral vasospasm and the potential to overcome infarction.
    Beck J; Raabe A
    Acta Neurochir Suppl; 2011; 110(Pt 2):147-50. PubMed ID: 21125461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2).
    Macdonald RL; Higashida RT; Keller E; Mayer SA; Molyneux A; Raabe A; Vajkoczy P; Wanke I; Bach D; Frey A; Marr A; Roux S; Kassell N
    Lancet Neurol; 2011 Jul; 10(7):618-25. PubMed ID: 21640651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dissociation of vasospasm-related morbidity and outcomes in patients with aneurysmal subarachnoid hemorrhage treated with clazosentan: a meta-analysis of randomized controlled trials.
    Shen J; Pan JW; Fan ZX; Xiong XX; Zhan RY
    J Neurosurg; 2013 Jul; 119(1):180-9. PubMed ID: 23641823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clazosentan to overcome neurological ischemia and infarction occurring after subarachnoid hemorrhage (CONSCIOUS-1): randomized, double-blind, placebo-controlled phase 2 dose-finding trial.
    Macdonald RL; Kassell NF; Mayer S; Ruefenacht D; Schmiedek P; Weidauer S; Frey A; Roux S; Pasqualin A;
    Stroke; 2008 Nov; 39(11):3015-21. PubMed ID: 18688013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dissociation of vasospasm and secondary effects of experimental subarachnoid hemorrhage by clazosentan.
    Sabri M; Ai J; Macdonald RL
    Stroke; 2011 May; 42(5):1454-60. PubMed ID: 21454820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different effects of clazosentan on consequences of subarachnoid hemorrhage in rats.
    Chen G; Tariq A; Ai J; Sabri M; Jeon HJ; Tang EJ; Lakovic K; Wan H; Macdonald RL
    Brain Res; 2011 May; 1392():132-9. PubMed ID: 21466789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Update on the Efficacy and Safety Profile of Clazosentan in Cerebral Vasospasm After Aneurysmal Subarachnoid Hemorrhage: A Meta-Analysis.
    Song J; Xue YQ; Wang YJ; Xu P; Sun DK; Chen W
    World Neurosurg; 2019 Mar; 123():e235-e244. PubMed ID: 30496924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clazosentan: an endothelin receptor antagonist for treatment of vasospasm after subarachnoid hemorrhage.
    Macdonald RL
    Expert Opin Investig Drugs; 2008 Nov; 17(11):1761-7. PubMed ID: 18922111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clazosentan for patients with subarachnoid haemorrhage: lessons learned.
    Wong GK; Poon WS
    Lancet Neurol; 2011 Oct; 10(10):871; author reply 871-2. PubMed ID: 21939894
    [No Abstract]   [Full Text] [Related]  

  • 13. Thick and Diffuse Subarachnoid Blood as a Treatment Effect Modifier of Clazosentan After Subarachnoid Hemorrhage.
    Mayer SA; Aldrich EF; Bruder N; Hmissi A; Macdonald RL; Viarasilpa T; Marr A; Roux S; Higashida RT
    Stroke; 2019 Oct; 50(10):2738-2744. PubMed ID: 31394993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversal of Vasospasm with Clazosentan After Aneurysmal Subarachnoid Hemorrhage: A Pilot Study.
    Higashida RT; Bruder N; Gupta R; Guzman R; Hmissi A; Marr A; Mayer SA; Roux S; Weidauer S; Aldrich EF
    World Neurosurg; 2019 Aug; 128():e639-e648. PubMed ID: 31054336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomised trial of clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid hemorrhage undergoing surgical clipping (CONSCIOUS-2).
    Macdonald RL; Higashida RT; Keller E; Mayer SA; Molyneux A; Raabe A; Vajkoczy P; Wanke I; Bach D; Frey A; Marr A; Roux S; Kassell N
    Acta Neurochir Suppl; 2013; 115():27-31. PubMed ID: 22890639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preventive Effect of Clazosentan against Cerebral Vasospasm after Clipping Surgery for Aneurysmal Subarachnoid Hemorrhage in Japanese and Korean Patients.
    Fujimura M; Joo JY; Kim JS; Hatta M; Yokoyama Y; Tominaga T
    Cerebrovasc Dis; 2017; 44(1-2):59-67. PubMed ID: 28463833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of clazosentan in patients with aneurysmal subarachnoid hemorrhage: a meta-analysis of randomized controlled trials.
    Wang X; Li YM; Li WQ; Huang CG; Lu YC; Hou LJ
    PLoS One; 2012; 7(10):e47778. PubMed ID: 23082215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endothelin receptor antagonists for aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis update.
    Vergouwen MD; Algra A; Rinkel GJ
    Stroke; 2012 Oct; 43(10):2671-6. PubMed ID: 22871682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clazosentan (AXV-034343), a selective endothelin A receptor antagonist, in the prevention of cerebral vasospasm following severe aneurysmal subarachnoid hemorrhage: results of a randomized, double-blind, placebo-controlled, multicenter phase IIa study.
    Vajkoczy P; Meyer B; Weidauer S; Raabe A; Thome C; Ringel F; Breu V; Schmiedek P
    J Neurosurg; 2005 Jul; 103(1):9-17. PubMed ID: 16121967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clazosentan for Aneurysmal Subarachnoid Hemorrhage: An Updated Meta-Analysis with Trial Sequential Analysis.
    Cho SS; Kim SE; Kim HC; Kim WJ; Jeon JP
    World Neurosurg; 2019 Mar; 123():418-424.e3. PubMed ID: 30508597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.